|
|||||
|
|
Current status of proteomics of esophageal carcinoma |
|
| Authors: | Norihisa Uemura Tadashi Kondo |
| Institution: | 1. Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan;2. Division of Rare Cancer Research, Department of Innovative Seeds Evaluation, National Cancer Center Research Institute, Tokyo, Japan |
| Abstract: | Introduction: Esophageal cancer (EC) is one of the most common causes of cancer-related death worldwide. Identifying suitable biomarkers for early diagnosis as well as predicting lymph node metastasis, prognosis and the therapeutic response of EC is essential for the effective and efficient management for EC. There is an urgent need to develop effective, novel approaches for patients who do not respond to conventional treatment. Areas covered: EC is characterized by the presence of two main histological types such as squamous cell carcinoma and adenocarcinoma, which differ in their response to treatments and prognosis. Thus, this review describes the latest research into biomarkers and novel treatment targets generated by cancer proteomics for the two main histological types. Finally, the main difficulties facing the translation of biomarkers and novel treatment targets into the clinical settings are discussed. Expert commentary: EC proteomics have provided useful results and, after their validation, novel clinical tools should be developed to improve the clinical outcomes for EC patients. |
| Keywords: | Biomarker early diagnosis esophageal cancer lymph node metastasis prognosis proteomics target therapy therapeutic response |